AnodyneWiki

3,4-Methylenedioxymethamphetamine

MDMA
3,4-Methylenedioxymethamphetamine
Salts
[]
3,4-Methylenedioxymethamphetamine hydrochloride
3,4-Methylenedioxymethamphetamine hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass193.24 g/mol [1]
AppearanceOil [1]
Boiling pointBP: 100-110 °C at 0.4 mmHg [1]
Predicted LogP2.2 [1]
Structural Identifiers
[]
Molecular formulaC11H15NO2
IUPAC name1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
SMILESCC(CC1=CC2=C(C=C1)OCO2)NC
InChIInChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3
InChIKeySHXWCVYOXRDMCX-UHFFFAOYSA-N
CAS number42542-10-9
UNIIKE1SEN21RM
PubChem CID1615
Pharmacokinetics[]
OnsetOral: 30–45 min
Elimination half-lifeMDMA: 8.7 (range 4.6–16) hours, (S)-MDMA: 5.1 (range 3.5–7.4) hours, (R)-MDMA: 11 (range 5.1–24) hours[3]
Duration of action3–6 hours
MetabolismLiver, CYP450 extensively involved, including CYP2D6
ExcretionKidney
Routes of administrationCommon: By mouth, Uncommon: Insufflation, inhalation, injection, rectal[4][5]
Dependence liabilityPhysical: Not typical, Psychological: Moderate[6][7]
Addiction liabilityLow–moderate[8][9][10]
Toxicity
[]
Guinea:
- pig ip: 98 mg/kg /MDMA
Mouse:
- ip: 97 mg/kg /MDMA
Rat:
- ip: 49 mg/kg /MDMA
 [1]
Dosing[]
Insufflated
[]
Light≤ 31.4 mg(25x - 27.5%)
Common31.4 - 50 mg(31x - 34.1%)
Strong50 - 65 mg(13x - 14.3%)
Heavy65 - 80 mg(15x - 16.5%)
Extreme80 mg +(7x - 7.7%)
Oral
[]
Light≤ 74.6 mg(22x - 36.1%)
Common74.6 - 100 mg(14x - 23.0%)
Strong100 - 120 mg(10x - 16.4%)
Heavy120 - 200 mg(9x - 14.8%)
Extreme200 mg +(6x - 9.8%)
Intrarectal
[]
Light≤ 86.3 mg(2x - 50.0%)
Common86.3 - 95 mg
Strong95 - 110 mg(2x - 50.0%)
Heavy110 mg
Extreme110 mg +
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki)
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

3,4-Methylenedioxymethamphetamine (also known as Ecstasy, Midomafetamine, Methylenedioxymethamphetamine, DL-(3,4-Methylenedioxy)methamphetamine, N-methyl-3,4-methylenedioxyamphetamine, (RS)-3,4-(methylenedioxy)methamphetamine, N,α-Dimethyl-1,3-benzodioxole-5-ethanamine, midomafetamina, Methylenedioxymetamphetamine or Methylenedioxymethamfetamine) is a antidepressant and depressant substance of the 3,4-methylenedioxyphenethylamine and amphetamine class.

Chemistry

Salts []

3,4-Methylenedioxymethamphetamine is typically found in the form of its hydrochloride salt.

 []

3,4-Methylenedioxymethamphetamine is a racemic mixture of the (optical activity ( + / - )).

Stereoisomers from PubChem

3,4-Methylenedioxymethamphetamine matches Lipinski's rule of five.

There are currently 14 reagent-interactions on

ReagentColor changeDescription
Marquisinstant purple/brown > black
Meckeinstant green > blue/black
Mandelininstant purple/blue > black
Liebermanninstant black
Froehdeinstant black
Robadopeno pink color change
Simon'sinstant dark blue
Ehrlichno color change
Hofmannno color change
Scottno color change
Morrispale green
Zimmermannno change / faint yellow
Gallicgreen>brown
Folinorange

Pharmacology

Mechanism of action []

It enters neurons via carriage by the monoamine transporters. Once inside, MDMA inhibits the vesicular monoamine transporter, which results in increased concentrations of serotonin, norepinephrine, and dopamine into the cytoplasm, and induces their release by reversing their respective transporters through a process known as phosphorylation. It also acts as a weak 5-HT1 and 5-HT2 receptor agonist. MDMA's unusual entactogenic effects have been hypothesized to be, at least partly, the result of indirect oxytocin secretion via activation of the serotonin system. Oxytocin is a hormone released following events like hugging, orgasm, and childbirth, and is thought to facilitate bonding and the establishment of trust. Based on studies in rats, MDMA is believed to cause the release of oxytocin, at least in part, by both directly and indirectly agonizing the serotonin 5-HT1A receptor. [1]

Prodrugs of 3,4-methylenedioxymethamphetamine: N-(L-Lysinamidyl)-3,4-methylenedioxymethamphetamine.

Subjective effects []

0xea / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Oral (100mg)
    Onset: 1 h
    Comeup: ~ 30 m
    Duration: ~ 6 h
  • Intravenous (70 - 165mg)
    Onset: 15 - 30 s
    Comeup: 1 - 5 m
    Duration: 30 - 60 m
Classes:Forms:
  • Hydrochloride
Effects:
a1ko / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Insufflated
  • Oral
bonzi / 3,4-Methylenedioxymethamphetamine []
emily / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Oral (40 - 91mg)
  • Insufflated (22mg)
magnus / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Oral
  • Insufflated
Forms:
  • Hydrochloride
Effects:
Mere / 3,4-Methylenedioxymethamphetamine []
michalina / 3,4-Methylenedioxymethamphetamine []
Effects:
  • strongly empathetic
  • stimulation
  • euphoria
  • dehydration
  • teeth grinding
nervewing / 3,4-Methylenedioxymethamphetamine []
ninerik / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Insufflated (40mg)
Classes:Effects:Odor:
  • Liquorice
Notes:
  • Hurts less than 2C-B when insufflated, but still stings slightly
x86pup / 3,4-Methylenedioxymethamphetamine []
Routes:
  • Oral

Experience reports

Erowid

There are currently 30 experience reports involving 3,4-methylenedioxymethamphetamine on : []

Reddit

There are currently 50 trip reports involving 3,4-methylenedioxymethamphetamine on : []

 []

  • Australia: 3,4-Methylenedioxymethamphetamine is a S8 (PTSD), S9 (all other uses).
  • Brazil: 3,4-Methylenedioxymethamphetamine is a F2.[11]
  • Canada: 3,4-Methylenedioxymethamphetamine is a Schedule I.
  • Germany: 3,4-Methylenedioxymethamphetamine is a Anlage I under the "Betäubungsmittelgesetz (BtMG)".
  • New Zealand: 3,4-Methylenedioxymethamphetamine is a Class B.
  • United Kingdom: 3,4-Methylenedioxymethamphetamine is a Class A under the "Misuse of Drugs Act 1971".
  • United States: 3,4-Methylenedioxymethamphetamine is a Schedule I under the "Controlled Substances Act".
  • United Nations: 3,4-Methylenedioxymethamphetamine is a Psychotropic Schedule I.
  • European Union: 3,4-Methylenedioxymethamphetamine is a Fully prohibited.
  • Other: 3,4-Methylenedioxymethamphetamine is a SE: Förteckning I.[12]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 1615, 3,4-Methylenedioxymethamphetamine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/1615
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. 3,4-Methylenedioxymethamphetamine. UNII: KE1SEN21RM. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/KE1SEN21RM
  3. Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, Luethi D, Liechti ME. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants. Neuropsychopharmacology. August 2024; 50(2):362–371. PMID 39179638. https://doi.org/10.1038/s41386-024-01972-6
  4. Methylenedioxymethamphetamine (MDMA or 'Ecstasy'). EMCDDA. http://www.emcdda.europa.eu/publications/drug-profiles/mdma
  5. Methylenedioxymethamphetamine (MDMA, ecstasy). Drugs and Human Performance Fact Sheets. http://www.nhtsa.dot.gov/people/injury/research/job185drugs/methylenedioxymethamphetamine.htm
  6. Palmer RB. Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants. John Wiley & Sons. 2012. https://books.google.com/books?id=OWFiVaDZnkQC&pg=PA139
  7. Upfal J. Australian Drug Guide: The Plain Language Guide to Drugs and Medicines of All Kinds. Black Inc. 2022.
  8. Malenka RC, Nestler EJ, Hyman SE. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. McGraw-Hill Medical. 2009.
  9. Betzler F, Viohl L, Romanczuk-Seiferth N. Decision-making in chronic ecstasy users: a systematic review. The European Journal of Neuroscience. January 2017; 45(1):34–44. PMID 27859780. https://doi.org/10.1111/ejn.13480
  10. Jerome L, Schuster S, Yazar-Klosinski BB. Can MDMA play a role in the treatment of substance abuse?. Current Drug Abuse Reviews. March 2013; 6(1):54–62. PMID 23627786. http://pdfs.semanticscholar.org/33fd/4f5decd405dee8d4f280a9158bfb16ae6e27.pdf
  11. Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-07-24. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451
  12. Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Swedish Medical Products Agency. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingok2026-11-20 05:22:32
drugsprook2026-11-20 05:22:28
erowidok2026-11-20 05:22:30
gsrsok2026-11-20 05:22:29
hmdbmissing (hmdb.ca refused automated access to HMDB0254382)2026-11-20 05:22:28
keggok2026-11-20 05:22:31
pubchemok2026-11-20 05:22:26
redditok2026-11-20 05:22:28
sidermissing (not in SIDER)2026-11-20 05:22:28
structureok2026-11-20 05:22:28
wikipediaok2026-11-20 05:22:28